Arbutus Biopharma Corporation (NASDAQ:ABUS) Files An 8-K Submission of Matters to a Vote of Security Holders

ME Staff 8-k
-
0

Arbutus Biopharma Corporation (NASDAQ:ABUS) Files An 8-K Submission of Matters to a Vote of Security Holders

Item 5.07. Submission of Matters to a Vote of Security Holders.

On May 24, 2017, the Corporation held its Annual General Meeting
of Shareholders. At the meeting, shareholders voted in favor of
all items of business, as indicated below:
Proposal 1. The Corporations shareholders voted to elect the
following persons to the board of directors of the Corporation,
each to serve until the 2018 Annual General Meeting:
Nominee
Votes For
% For
Votes Withheld
% Withheld
Broker Non- Votes
Vivek Ramaswamy
25,146,794
99.63
93,349
0.37
3,264,375
Mark J. Murray
25,097,915
99.44
142,228
0.56
3,264,375
Daniel D. Burgess
25,155,577
99.66
84,566
0.34
3,264,375
Herbert J. Conrad
25,150,938
99.65
89,205
0.35
3,264,375
Richard C. Henriques
25,153,648
99.66
86,495
0.34
3,264,375
Frank Karbe
25,145,200
99.62
94,943
0.38
3,264,375
Keith Manchester
25,108,567
99.48
131,576
0.52
3,264,375
William T. Symonds
25,152,619
99.65
87,524
0.35
3,264,375
Proposal 2. The Corporations shareholders voted to ratify the
appointment of KPMG LLP as independent auditor of the Corporation
for the fiscal year ended December 31, 2017:
Votes For
% For
Votes Against
% Against
Abstain
28,466,386
99.87
21,898
0.13
16,234
1


About Arbutus Biopharma Corporation (NASDAQ:ABUS)

Arbutus Biopharma Corporation, formerly Tekmira Pharmaceuticals Corporation, is a therapeutic solutions company. The Company is engaged in discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection (HBV), a disease of the liver caused by the hepatitis B virus (HBV). It is developing a pipeline focused on advancing Ribo Nucleic Acid interference therapeutics (RNAi) using its Lipid Nanoparticle technology. The Company’s lead RNAi HBV candidate, ARB-1467, eliminates HBV surface antigen expression in patients chronically infected with HBV. ARB-1467 is being developed as a multi-component RNAi therapeutic that targets various sites on the HBV genome. It is also developing small molecule covalently closed circular deoxyribonucleic acid (cccDNA) formation inhibitors, multiple small molecule orally bioavailable inhibitors of HBV surface antigen production and secretion, cccDNA epigenetic modifiers and stimulator of interferon genes agonists.

Arbutus Biopharma Corporation (NASDAQ:ABUS) Recent Trading Information

Arbutus Biopharma Corporation (NASDAQ:ABUS) closed its last trading session down -0.08 at 3.42 with 85,575 shares trading hands.